Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Neoplasms 282Carcinoma, Non-Small-Cell Lung 253Leukemia, Myeloid, Acute 190Breast Neoplasms 153Melanoma 151Neoplasm Metastasis 148Multiple Myeloma 127Recurrence 123Colorectal Neoplasms 119Lymphoma, Non-Hodgkin 114Lymphoma 113Leukemia, Lymphocytic, Chronic, B-Cell 108Pancreatic Neoplasms 99Ovarian Neoplasms 99Precursor Cell Lymphoblastic Leukemia-Lymphoma 91Leukemia 86Prostatic Neoplasms 83Lung Neoplasms 82Squamous Cell Carcinoma of Head and Neck 77Lymphoma, Large B-Cell, Diffuse 77Glioblastoma 73Carcinoma, Renal Cell 72Myelodysplastic Syndromes 68Lymphoma, Follicular 65Brain Neoplasms 60Lymphoma, Mantle-Cell 55Sarcoma 53Triple Negative Breast Neoplasms 52Stomach Neoplasms 52Head and Neck Neoplasms 52

Interventions

ribociclib 1LSZ102 1Alpelisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Terminated × Advanced or Metastatic ER+ Breast Cancer × Clear all
NCT02734615 2022-08-01

Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers

Novartis

Phase 1 Terminated
199 enrolled
Breast

Advanced or Metastatic ER+ Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡